Brief: Replimune Group Disagrees With FDA About Whether Rp1 BLA Data Set Is Enough To Allow The Medicine To Be Made Available To Advanced Cancer Patients
10/04/2026 22:11
April 10 (Reuters) - Replimune Group Inc REPL.O: REPLIMUNE GROUP: DISAGREES WITH FDA ABOUT WHETHER RP1 BLA DATA SET IS ENOUGH TO ALLOW THE MEDICINE TO BE MADE AVAILABLE TO ADVANCED CANCER PATIENTS REPLIMUNE GROUP: WE HAVE NO CHOICE BUT TO ELIMINATE JOBS, INCLUDING SUBSTANTIALLY SCALING BACK OUR U.S. BASED MANUFACTURING OPERATIONS REPLIMUNE: BASED ON FDA FEEDBACK, STARTED IGNYTE-3 TO SATISFY REGULATORY REQUIREMENT THAT CONFIRMATORY STUDY BE UNDERWAY FOR ACCELERATED APPROVAL Source text: ID:nGNX7W8lny Further company coverage: REPL.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Replimune
See all newsTrump picks White House adviser Heidi Overton to run FDA, source says (updated)
Brief: Replimune Group, Inc. Files For Mixed Shelf Size Not Disclosed
Brief: Replimune Reports Fiscal First Quarter 2027 Financial Results And Provides Corporate Update
Replimune Q1 net loss narrows as expenses decline
U.S. STOCKS ON THE MOVE-Microsoft, Coastal Financial, Eli Lilly